News|Articles|May 15, 2014
- Pharmaceutical Technology-05-15-2014
- Volume 2014 eBook
- Issue 2
Determining Cross-Contamination Risks in Multiproduct Biopharmaceutical Facilities
Author(s)Cynthia A. Challener
A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.
Advertisement
A global contract manufacturer of biologics discusses the increasing impact of health-based exposure limits in assessing cross-contamination risks.
Download
.
Articles in this issue
over 12 years ago
Potential Benefits Drive Interest in Continuous Manufacturingover 12 years ago
Continuous Bioprocessing Challengesover 12 years ago
Optimizing the Sterilization of Liquids in Sealed Containersover 12 years ago
Using Modular Systems in Biopharmaceutical Manufacturingover 12 years ago
Determining Protein Oxidation Induced During Fill-Finish Operationsover 12 years ago
Single-Use Technology in Parenteral Fill/FinishAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
A Capsule-in-Capsule Platform for Multi-Phase Release of Liquid and Solid Formulations
2
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
3
Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?
4
PharmTech Weekly Roundup—August 14, 2026
5